Cell Therapy Manufacturing
Africa · 3 shared keywords
Africa Allogeneic Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Cell Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Africa · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$14.9 Mn
Estimated value
Estimate 2025
$18.9 Mn
1.3% of the global market
Projected 2034
$155.3 Mn 723.6%
Adds $136.4 Mn over 9 forecast years
CAGR 2025–2034
26.4%
Faster than 93% of 180 Pharmaceuticals markets here
Key players
5
Companies profiled
- Africa is 1.34% of the global market.
- Among regions, the largest is North America at $596.0 Mn.
- Fastest growing: Africa (this report) at 26.4% a year.
- Africa ranks 6th of 6 by size among regions.
Market size projection
AfricaSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$136.4 Mn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $14.9 Mn | — | — |
| 2025 (base) | $18.9 Mn | +$3.9 Mn | — |
| 2026 (forecast) | $23.8 Mn | +$5.0 Mn | +26.4% |
| 2027 (forecast) | $30.1 Mn | +$6.3 Mn | +59.8% |
| 2028 (forecast) | $38.1 Mn | +$8.0 Mn | +101.9% |
| 2029 (forecast) | $48.1 Mn | +$10.1 Mn | +155.3% |
| 2030 (forecast) | $60.8 Mn | +$12.7 Mn | +222.7% |
| 2031 (forecast) | $76.9 Mn | +$16.1 Mn | +307.8% |
| 2032 (forecast) | $97.2 Mn | +$20.3 Mn | +415.5% |
| 2033 (forecast) | $122.8 Mn | +$25.7 Mn | +551.6% |
| 2034 (forecast) | $155.3 Mn | +$32.4 Mn | +723.6% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $1.41 Bn
-
US
$629.0 Mn
- North America $596.0 Mn
- APAC $329.0 Mn
- Europe $238.5 Mn
-
China
$102.7 Mn
-
Canada
$98.3 Mn
-
Japan
$80.4 Mn
-
Germany
$55.9 Mn
- Middle East $57.2 Mn
- Latin America $56.5 Mn
-
France
$39.7 Mn
-
Italy
$33.5 Mn
-
UK
$30.3 Mn
-
Spain
$30.2 Mn
-
Brazil
$30.7 Mn
-
India
$30.6 Mn
-
Ecuador
$28.9 Mn
-
Mexico
$22.7 Mn
-
Saudi Arabia
$23.0 Mn
-
Australia
$19.3 Mn
- Africa (this report) $18.9 Mn
-
New Zealand
$16.5 Mn
-
Russia
$13.1 Mn
-
South Africa
$8.3 Mn
-
UAE
$7.8 Mn
-
Egypt
$4.3 Mn
-
Philippines
$3.0 Mn
-
Hong Kong
$2.4 Mn
-
Malaysia
$2.0 Mn
-
Thailand
$1.7 Mn
-
Singapore
$1.6 Mn
-
Kenya
$1.1 Mn
The Africa Allogeneic Cell Therapy Market Analysis Executive Summary
Allogeneic cell therapies use cells from healthy donors to make ready-to-use treatments that do not have to be made for each patient.
Key segments of the allogeneic Cell Therapy market include cell type (T Cells, NK Cells and Stem Cells) and indication (Oncology, Autoimmune and Regenerative Medicine).
Africa Allogeneic Cell Therapy Market Dynamics
Market Growth Drivers
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the allogeneic Cell Therapy market.
Opportunity
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the allogeneic Cell Therapy market.
Market Restraints
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the allogeneic Cell Therapy market. Payers are still working out how to pay for one-time cures.
Competitive Landscape for Allogeneic Cell Therapy Market in Africa
The allogeneic Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Allogeneic Cell Therapy Market in Africa
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allogeneic Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Africa.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Allogeneic Cell Therapy right now, from free public sources.
Latest research 103 papers since 2021 (worldwide)
- Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy. Acta pharmaceutica Sinica. B, 2026
- Immune Evasion Strategies of Human Poxviruses: A Roadmap for Engineering Low-Immunogenic CAR-Based and iPSC-Derived Cell Products. Cells, 2026
- HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice. Cells, 2026
- Allogeneic Human Bone Marrow-Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study. The Kaohsiung journal of medical sciences, 2026
- Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications. Regenerative therapy, 2026
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Allogeneic Cell Therapy in context
Questions, answered with public data
- How much research is published on Allogeneic Cell Therapy?
- PubMed lists 103 papers added since January 2021 that match this market, worldwide.[1]
[1] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Free data on this topic
- Clinical trials: Cell and gene therapy
- New research: Cell and gene therapy
- FDA approvals and recalls: Cell and gene therapy
- NIH research grants: Cell and gene therapy
- EU medicine approvals: Cell and gene therapy
- US drug spending: Cell and gene therapy
- Clinical trials: Biologics and biosimilars
- New research: Biologics and biosimilars
From our blog
Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…